Last reviewed · How we verify
Montelukast (Low FeNO group)
Montelukast (Low FeNO group) is a Leukotriene receptor antagonist Small molecule drug developed by Hull University Teaching Hospitals NHS Trust. It is currently FDA-approved for Asthma (maintenance and acute treatment), Allergic rhinitis, Exercise-induced bronchoconstriction. Also known as: Montelukast.
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) to reduce airway inflammation and bronchoconstriction in asthma.
Montelukast blocks cysteinyl leukotriene receptors (CysLT1) to reduce airway inflammation and bronchoconstriction in asthma. Used for Asthma (maintenance and acute treatment), Allergic rhinitis, Exercise-induced bronchoconstriction.
At a glance
| Generic name | Montelukast (Low FeNO group) |
|---|---|
| Also known as | Montelukast |
| Sponsor | Hull University Teaching Hospitals NHS Trust |
| Drug class | Leukotriene receptor antagonist |
| Target | CysLT1 (cysteinyl leukotriene receptor type 1) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Immunology |
| Phase | FDA-approved |
Mechanism of action
Montelukast is a selective antagonist of the cysteinyl leukotriene type-1 (CysLT1) receptor. Leukotrienes are inflammatory mediators released by mast cells and eosinophils that promote airway constriction, mucus secretion, and eosinophil recruitment. By blocking these receptors, montelukast reduces inflammation and improves airflow in asthmatic patients, particularly those with low fractional exhaled nitric oxide (FeNO), suggesting a non-eosinophilic phenotype.
Approved indications
- Asthma (maintenance and acute treatment)
- Allergic rhinitis
- Exercise-induced bronchoconstriction
Common side effects
- Headache
- Influenza-like illness
- Abdominal pain
- Cough
- Neuropsychiatric events (rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Montelukast (Low FeNO group) CI brief — competitive landscape report
- Montelukast (Low FeNO group) updates RSS · CI watch RSS
- Hull University Teaching Hospitals NHS Trust portfolio CI
Frequently asked questions about Montelukast (Low FeNO group)
What is Montelukast (Low FeNO group)?
How does Montelukast (Low FeNO group) work?
What is Montelukast (Low FeNO group) used for?
Who makes Montelukast (Low FeNO group)?
Is Montelukast (Low FeNO group) also known as anything else?
What drug class is Montelukast (Low FeNO group) in?
What development phase is Montelukast (Low FeNO group) in?
What are the side effects of Montelukast (Low FeNO group)?
What does Montelukast (Low FeNO group) target?
Related
- Drug class: All Leukotriene receptor antagonist drugs
- Target: All drugs targeting CysLT1 (cysteinyl leukotriene receptor type 1)
- Manufacturer: Hull University Teaching Hospitals NHS Trust — full pipeline
- Therapeutic area: All drugs in Respiratory / Immunology
- Indication: Drugs for Asthma (maintenance and acute treatment)
- Indication: Drugs for Allergic rhinitis
- Indication: Drugs for Exercise-induced bronchoconstriction
- Also known as: Montelukast
- Compare: Montelukast (Low FeNO group) vs similar drugs
- Pricing: Montelukast (Low FeNO group) cost, discount & access